Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.

BACKGROUND:The World Health Organization recommends non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based antiretroviral therapy (ART) for children three years and older. In younger children, starting ART with lopinavir boosted with ritonavir (LPVr) results in lower risk of virological fail...

Full description

Bibliographic Details
Main Authors: Gerardo Alvarez-Uria, Raghavakalyan Pakam, Praveen Kumar Naik, Manoranjan Midde
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4169483?pdf=render
id doaj-7ad3a8cce45f4ac6b0d70179c514b67a
record_format Article
spelling doaj-7ad3a8cce45f4ac6b0d70179c514b67a2020-11-24T22:18:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0199e10806310.1371/journal.pone.0108063Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.Gerardo Alvarez-UriaRaghavakalyan PakamPraveen Kumar NaikManoranjan MiddeBACKGROUND:The World Health Organization recommends non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based antiretroviral therapy (ART) for children three years and older. In younger children, starting ART with lopinavir boosted with ritonavir (LPVr) results in lower risk of virological failure, but data in children three years and older are scarce, and long-term ART with LPVr is problematic in resource-poor settings. METHODOLOGY:Retrospective cohort of children three years and older who started triple ART including LPVr or a NNRTI between 2007 and 2013 in a rural setting in India. Children who started LPVr were switched to nevirapine-based ART after virological suppression. We analysed two outcomes, virological suppression (HIV-RNA <400 copies/ml) within one year of ART using logistic regression, and time to virological failure (HIV-RNA >1000 copies/ml) after virological suppression using Cox proportional hazard regression. A sensitivity analysis was performed using inverse probability of treatment weighting (IPTW) based of propensity score methods. FINDINGS:Of 325 children having a viral load during the first year of ART, 74/83 (89.2%) in the LPVr group achieved virological suppression versus 185/242 (76.5%) in the NNRTI group. In a multivariable analysis, the use of LPVr-based ART was associated with higher probability of virological suppression (adjusted odds ratio 3.19, 95% confidence interval [CI] 1.11-9.13). After IPTW, the estimated risk difference was 12.2% (95% CI, 2.9-21.5). In a multivariable analysis including 292 children who had virological suppression and available viral loads after one year of ART, children switched from LPVr to nevirapine did not have significant higher risk of virological failure (adjusted hazard ratio 1.18, 95% CI 0.36-3.81). CONCLUSIONS:In a cohort of HIV infected children three years and older in a resource-limited setting, an LPVr induction- nevirapine maintenance strategy resulted in more initial virological suppression and similar incidence of virological failure after initial virological suppression than NNRTI-based regimens.http://europepmc.org/articles/PMC4169483?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Gerardo Alvarez-Uria
Raghavakalyan Pakam
Praveen Kumar Naik
Manoranjan Midde
spellingShingle Gerardo Alvarez-Uria
Raghavakalyan Pakam
Praveen Kumar Naik
Manoranjan Midde
Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
PLoS ONE
author_facet Gerardo Alvarez-Uria
Raghavakalyan Pakam
Praveen Kumar Naik
Manoranjan Midde
author_sort Gerardo Alvarez-Uria
title Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
title_short Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
title_full Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
title_fullStr Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
title_full_unstemmed Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
title_sort induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in hiv infected children three years and older.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description BACKGROUND:The World Health Organization recommends non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based antiretroviral therapy (ART) for children three years and older. In younger children, starting ART with lopinavir boosted with ritonavir (LPVr) results in lower risk of virological failure, but data in children three years and older are scarce, and long-term ART with LPVr is problematic in resource-poor settings. METHODOLOGY:Retrospective cohort of children three years and older who started triple ART including LPVr or a NNRTI between 2007 and 2013 in a rural setting in India. Children who started LPVr were switched to nevirapine-based ART after virological suppression. We analysed two outcomes, virological suppression (HIV-RNA <400 copies/ml) within one year of ART using logistic regression, and time to virological failure (HIV-RNA >1000 copies/ml) after virological suppression using Cox proportional hazard regression. A sensitivity analysis was performed using inverse probability of treatment weighting (IPTW) based of propensity score methods. FINDINGS:Of 325 children having a viral load during the first year of ART, 74/83 (89.2%) in the LPVr group achieved virological suppression versus 185/242 (76.5%) in the NNRTI group. In a multivariable analysis, the use of LPVr-based ART was associated with higher probability of virological suppression (adjusted odds ratio 3.19, 95% confidence interval [CI] 1.11-9.13). After IPTW, the estimated risk difference was 12.2% (95% CI, 2.9-21.5). In a multivariable analysis including 292 children who had virological suppression and available viral loads after one year of ART, children switched from LPVr to nevirapine did not have significant higher risk of virological failure (adjusted hazard ratio 1.18, 95% CI 0.36-3.81). CONCLUSIONS:In a cohort of HIV infected children three years and older in a resource-limited setting, an LPVr induction- nevirapine maintenance strategy resulted in more initial virological suppression and similar incidence of virological failure after initial virological suppression than NNRTI-based regimens.
url http://europepmc.org/articles/PMC4169483?pdf=render
work_keys_str_mv AT gerardoalvarezuria inductionwithlopinavirbasedtreatmentfollowedbyswitchtonevirapinebasedregimenversusnonnucleosidereversetranscriptaseinhibitorsbasedtreatmentforfirstlineantiretroviraltherapyinhivinfectedchildrenthreeyearsandolder
AT raghavakalyanpakam inductionwithlopinavirbasedtreatmentfollowedbyswitchtonevirapinebasedregimenversusnonnucleosidereversetranscriptaseinhibitorsbasedtreatmentforfirstlineantiretroviraltherapyinhivinfectedchildrenthreeyearsandolder
AT praveenkumarnaik inductionwithlopinavirbasedtreatmentfollowedbyswitchtonevirapinebasedregimenversusnonnucleosidereversetranscriptaseinhibitorsbasedtreatmentforfirstlineantiretroviraltherapyinhivinfectedchildrenthreeyearsandolder
AT manoranjanmidde inductionwithlopinavirbasedtreatmentfollowedbyswitchtonevirapinebasedregimenversusnonnucleosidereversetranscriptaseinhibitorsbasedtreatmentforfirstlineantiretroviraltherapyinhivinfectedchildrenthreeyearsandolder
_version_ 1725782465176403968